Skip to Content
Merck
  • Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation.

Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation.

Scientific reports (2014-06-12)
Shigemi Kimura, Kowasi Yoshioka
ABSTRACT

The ZHTc6-MyoD embryonic stem cell line expresses the myogenic transcriptional factor MyoD under the control of a tetracycline-inducible promoter. Following induction, most of the ZHTc6-MyoD cells differentiate to myotubes. However, a small fraction does not differentiate, instead forming colonies that retain the potential for myocyte differentiation. In our current study, we found that parathyroid hormone type 1 receptor (PTH1R) expression in colony-forming cells at 13 days after differentiation was higher than that in the undifferentiated ZHTc6-MyoD cells. We also found that PTH1R expression was required for myocyte differentiation, and that parathyroid hormone accelerated the differentiation. Our analysis of human and mouse skeletal muscle tissues showed that most cells expressing PTH1R also expressed Pax7 and CD34, which are biomarkers of satellite cells. Furthermore, we found that parathyroid hormone treatment significantly improved muscle weakness in dystrophin-deficient mdx mice. This is the first report indicating that PTH1R and PTH accelerate myocyte differentiation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ganciclovir, ≥99% (HPLC), powder
Sigma-Aldrich
MISSION® esiRNA, targeting human TMEM131
Ganciclovir, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Anti-PTH1R antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
MISSION® esiRNA, targeting human NRGN
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Tmem131